Kursinformationen zu Lord Abbett Global Health Care Fund - Class A USD Accumulating
- NAV in CHF
- 12.96
- Tagesveränderung relativ
- +0.31%
- Tagesveränderung absolut
- 0.04
- NAV Vortag
- 12.92
- Letzter Handel
- 28.09.2026
- Ausgabekommissionen
- +5.00%
- Verwaltungsgebühr
- +1.52%
- OGC
- 0.00 %
- Monatsbericht
- -
- Halbjahresbericht
- -
- Jahresbericht
- -
- Vollständiger Fondsprospekt
- -
- Gesetzl. Publikationen
The investment objective of the Fund is to seek long-term capital appreciation. Under normal conditions, the Fund pursues its investment objective by investing at least 80% of its net assets in equity and equity related securities of health care-related companies. The Fund considers health care-related companies to be those companies that operate in, or are related to, the major subsectors of the health care sector, including pharmaceuticals, biotechnology, health care technology, life sciences tools and services, health care equipment and supplies, and health care providers and services. Equity securities in which the Fund may invest include common stocks, preferred stocks, equity interests in trusts (including real estate investment trusts and privately offered trusts), partnerships, joint ventures, limited liability companies and other instruments convertible or exercisable into the foregoing such as convertible bonds (excluding contingent convertible bonds) and warrants. The Fund may invest in U.S. and non-U.S. (including up to 20% of net assets in emerging market) companies, the securities of which may be traded on U.S. or non-U.S. securities exchanges (or may not be traded on any securities exchange), may be denominated in the U.S. dollar or other currencies, and may include American Depositary Receipts and other similar depositary receipts. The Fund also may invest in supranational organizations. The Fund has no geographical limitations on investments or any limit on the amount of assets that may be invested in any single country.
| Zeitraum | Performance | Volatilität | Sharpe Ratio | Bester Monat | Schlecht. Monat | Max Verlust |
|---|---|---|---|---|---|---|
| YTD | +6.75% | +18.87% | +0.35% | +7.39% | -4.72% | -11.50% |
| 6 Monate | +17.29% | +19.44% | +1.80% | +7.39% | -4.72% | -6.76% |
| 1 Jahr | +22.84% | +18.00% | +1.13% | +9.97% | -4.72% | -13.39% |
| 3 Jahre | - | - | - | - | - | - |
| 5 Jahre | - | - | - | - | - | - |
- ISIN
- IE000H7H0VY6
- Valor
- 127166454
- Währung
- USD
- Fondstyp
- Aktienfonds
- Ertragsart
- thesaurierend
- Anlageschwerpunkt
- Branche Gesundheit/Pharma
- Anlageregion
- weltweit
- Domizil
- -
- Vertriebszulassung
- Irland
- Auflagedatum
- 20.06.2023
- Fondsvolumen
- 2'806'709.33
- Geschäftsjahresbeginn
- 01.02.2026
- Benchmark
- -
- Fondsgesellschaft
- Lord Abbett (IE)
- Eli Lilly & Co
- 8.80 %
- Argenx SE
- 4.10 %
- AstraZeneca PLC
- 3.50 %
- Gilead Sciences Inc
- 3.50 %
- Tarsus Pharmaceuticals Inc
- 3.10 %
- Natera Inc
- 3.00 %
- Guardant Health Inc
- 2.80 %
- Cencora Inc
- 2.70 %
- EssilorLuxottica SA
- 2.70 %
- Abivax SA
- 2.40 %
- Pharmazeutika/Biotechnologie
- 39.30 %
- Pharmazeutika Produktion
- 26.70 %
- Gesundheitswesen
- 17.80 %
- Medizinische Produkte/Instrumente
- 14.30 %